\
&
Contact us
\
&
Contact us
This was 1 year ago
Locationon-line
ProgrammesThere is 1 attachment connected to this article.
Attachments are only accessible for people with an account on the NCP Flanders website.
The webinar will deal with "Towards the implementation of the New European Research Area:
status, achievements, next steps" presented by Anna Panagopoulou, the Director of Directorate ERA & Innovation in DG RTD, European Commission. More details in the attached file.
Register before the 15th of May at 15:00 CET to receive the link to the webinar room.
Click this link to register: https://forms.office.com/e/LdzxfD2maQ
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
